We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials
News

Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials

Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials
News

Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncolytics Biotech Inc. has announced that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Orlando, Florida May 29-June 2, 2009. The abstracts are available on the ASCO website at www.asco.org.

REOLYSIN poster presentations:

Dr. Monica Mita and colleagues are scheduled to deliver a poster presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type Reovirus in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung."

Dr. Johann de Bono and colleagues are scheduled to deliver a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts) with Advanced Cancer."

Dr. Sanjay Goel and colleagues are scheduled to deliver a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors."
Advertisement